Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 213

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Open access
Pant, Shubham, Schuler, Martin, Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Reardon, David A, Massard, Christophe, Minchom, Anna, Lugowska, Iwona, Carranza, Omar, Arnold, Dirk, Gutierrez, Martin, Winter, Helen, Stuyckens, Kim, Crow, Lauren, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Santiago-Walker, Ademi, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann, Carranza, Omar, Greco, Martin Alberto, Coward, Jim, Joshua, Anthony, Karapetis, Christos, Hart, Christopher, Zhang, Alison, Prenen, Hans, Goeminne, Jean-Charles, Machiels, Jean-Pascal, Rottey, Sylvie, Corassa, Marcelo, Molin, Graziela Zibetti Dal, Tiscoski, Katsuki, Jardim, Denis Leonardo Fontes, Mak, Milena, Fu, Wei, Yao, Herui, Huang, Jing, Jiang, Haiping, Qin, Shukui, Chen, Baoshi, Yan, Dong, Yang, Yu, Loriot, Yohann, Le Tourneau, Christophe, Penel, Nicolas, Salas, Sébastien, Blay, Jean-Yves, Brachet, Pierre-Emmanuel, Durando, Xavier, Emambux, Sheik, Ravaud, Alain, Folprecht, Gunnar, Arnold, Dirk, Schuler, Martin, Ahrens, Marit, Golf, Alexander, Haag, Georg Martin, Lordick, Florian, Desuki, Alexander, Cazzaniga, Marina, Ciardiello, Fortunato, Milella, Michele, Koyama, Takafumi, Hirooka, Yoshiki, Okamoto, Wataru, Aogi, Kenjiro, Kuboki, Yasutoshi, Lee, Jungyun, Kim, Sung-Bae, Ahn, Myung-Ju, Chang, Jong Hee, Kim, Yong-Man, Nam, Do-Hyun, Park, Jae-Sung, Lugowska, Iwona, Paz-Ares, Luis, Moreno, Victor, Cervantes, Andres, Calvo, Mariona, Falcon, Alejandro, Gonzalez, Antonio, Tabernero, Josep, Martinez Bueno, Alejandro, García-Corbacho, Javier, Longo, Federico, Yen, Chia-Jui, Chen, Jen-Shi, Hou, Ming-Feng, Chao, Yee, Rau, Kun-Ming, Chiu, Tai-Jan, Feng, Yin-Hsun, Hsu, Chih-Hung, Huang, Wen-Tsung, Lai, Kuan-Ming, Yeh, Su-peng, Palmer, Daniel, Minchom, Anna, Winter, Helen, Welsh, Liam, Plummer, Ruth, Iyer, Gopakumar, Gutierrez, Martin, Bilen, Mehmet, Arrowsmith, Edward, Pant, Shubham, Spigel, David Robert, Zandberg, Dan Paul, Doroshow, Deborah, Lu-Emerson, Christine, Moezi, Mehdi, Paulson, Scott, Reardon, David, Ward, Patrick, Chaves, Jorge, Grigg, Claud, Hussein, Atif, Manda, Sudhir, Monticelli, Michael, Qamar, Rubina, Richey, Stephen L, Tamura, David, Wilks, Sharon · 2023 · The Lancet Oncology

Abstract

Summary Background FGFR alterations (alt) are reported across various malignancies and may act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and efficacy of erdafitinib in a phase 2 study of previously treated patients with FGFR-altered advanced solid tumours. Methods Patients were aged ≥12 years with advanced or metastatic tumours of any histology, except urothelial cancer, with predefined FGFR1–4alt (mutations/fusions per local/central testing) and disease progression on ≥1 prior line of systemic therapy and no alternative standard therapy and an Eastern Cooperative Oncology Group performance status of 0–1. Patients received once-daily oral erdafitinib (8 mg/day with provision for pharmacodynamically guided uptitration to 9 mg/day) on a continuous 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate (ORR) by independent review committee per RECIST version 1·1 and RANO. This primary analysis was conducted on the treated population of the Broad Panel Cohort. This ongoing study is registered with ClinicalTrials.gov, number NCT04083976. Findings RAGNAR initiated on Dec 5, 2019, and evaluated 217 erdafitinib-treated patients. 97 (45%) and 120 (55%) of the 217 patients were female and male, respectively. The data cutoff was Aug 15, 2022. At a median follow-up of 17·9 months (IQR 13·6–23·9), an ORR of 30% (95% CI 24–36) was observed in 64 of 217 patients across 16 distinct tumours. The most common grade 3–5 (all grade 3) treatment-emergent adverse events of any causality were stomatitis in 25 (12%), anaemia in 18 (8%), and palmar-plantar erythrodysaesthesia syndrome in 12 (6%) of 217 patients. The most commonly occurring serious treatment-related adverse events (grade 3 or higher) were stomatitis in 4 (2%) and diarrhoea in 2 (1%) of 217 patients. There were no treatment-related deaths. Interpretation RAGNAR results demonstrate clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options. These results support the continued development of FGFR inhibitors in patients with advanced solid tumours. Funding Janssen Research & Development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(23)00275-9

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 213

Metadata

Authors
Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., Tabernero, J., Reardon, D. A., Massard, C., Minchom, A., Lugowska, I., Carranza, O., Arnold, D., Gutierrez, M., Winter, H., Stuyckens, K., Crow, L., Najmi, S., Hammond, C., Thomas, S., Santiago-Walker, A., Triantos, S., Sweiti, H., Loriot, Y., Carranza, O., Greco, M. A., Coward, J., Joshua, A., Karapetis, C., Hart, C., Zhang, A., Prenen, H., Goeminne, J.-C., Machiels, J.-P., Rottey, S., Corassa, M., Molin, G. Z. D., Tiscoski, K., Jardim, D. L. F., Mak, M., Fu, W., Yao, H., Huang, J., Jiang, H., Qin, S., Chen, B., Yan, D., Yang, Y., Loriot, Y., Le Tourneau, C., Penel, N., Salas, S., Blay, J.-Y., Brachet, P.-E., Durando, X., Emambux, S., Ravaud, A., Folprecht, G., Arnold, D., Schuler, M., Ahrens, M., Golf, A., Haag, G. M., Lordick, F., Desuki, A., Cazzaniga, M., Ciardiello, F., Milella, M., Koyama, T., Hirooka, Y., Okamoto, W., Aogi, K., Kuboki, Y., Lee, J., Kim, S.-B., Ahn, M.-J., Chang, J. H., Kim, Y.-M., Nam, D.-H., Park, J.-S., Lugowska, I., Paz-Ares, L., Moreno, V., Cervantes, A., Calvo, M., Falcon, A., Gonzalez, A., Tabernero, J., Martinez Bueno, A., García-Corbacho, J., Longo, F., Yen, C.-J., Chen, J.-S., Hou, M.-F., Chao, Y., Rau, K.-M., Chiu, T.-J., Feng, Y.-H., Hsu, C.-H., Huang, W.-T., Lai, K.-M., Yeh, S.-P., Palmer, D., Minchom, A., Winter, H., Welsh, L., Plummer, R., Iyer, G., Gutierrez, M., Bilen, M., Arrowsmith, E., Pant, S., Spigel, D. R., Zandberg, D. P., Doroshow, D., Lu-Emerson, C., Moezi, M., Paulson, S., Reardon, D., Ward, P., Chaves, J., Grigg, C., Hussein, A., Manda, S., Monticelli, M., Qamar, R., Richey, S. L., Tamura, D., & Wilks, S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2023-08
Volume
24
Issue
8
Pages
925-935
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4385443485
Cited by
213
References
3
FWCI
15.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00275-9
The paper
Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., Tabernero, J., Reardon, D. A., Massard, C., Minchom, A., Lugowska, I., Carranza, O., Arnold, D., Gutierrez, M., Winter, H., Stuyckens, K., Crow, L., Najmi, S., Hammond, C., . . . Wilks, S. (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00275-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.